This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Leveraged ETFs of Last Week
by Sanghamitra Saha
Leveraged gold miners and treasury ETFs gained last week despite a market crash.
The Zacks Analyst Blog Highlights: Microvision, Veritone, Remark, Novavax and DCP
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microvision, Veritone, Remark, Novavax and DCP
Growth Investing Leads in 1H: 5 Top ETFs & Stocks
by Sweta Killa
Growth investing took a lead so far this year courtesy of massive money flowing into the economy.
The Zacks Analyst Blog Highlights: Zoom Video, Quidel, Zscaler, Datadog and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Zoom Video, Quidel, Zscaler, Datadog and Novavax
Fears of a Second Wave of Coronavirus are Aiding These 5 Stocks
by Anirudha Bhagat
Here we pick five stocks which have potentials to gain in situations if the stock market is hit by the second wave of the coronavirus pandemic.
Wall Street Readies for Best Quarter Ever: 5 Picks
by Tirthankar Chakraborty
The S&P 500 is up 21.2% so far in Q2 and is on pace for its biggest quarterly gain since Q1 of 1975. Similarly, the Nasdaq is up 31.6% since the end of Q1, putting it on pace for its second-best quarter ever.
5 Top-Ranked Stocks That Made Nasdaq Outperform in 1H
by Sweta Killa
The tech-heavy Nasdaq Composite Index has outperformed so far this year, having gained 12% in comparison to losses of 3.5%for the S&P 500 and 8.8% for Dow Jones.
5 Nasdaq Stocks That Have Returned More Than 100% YTD
by Aniruddha Ganguly
Here we discuss five Nasdaq-listed stocks that have gained more than 100% year to date and are well-poised to grow further on solid prospects.
Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Novavax, Inc. (NVAX).
Novavax (NVAX) Up More Than 1200% Year to Date: Here's Why
by Zacks Equity Research
Novavax's (NVAX) coronavirus vaccine candidate NVX-CoV2373 enters clinical studies. The company also plans to file a BLA on its influenza vaccine candidate, NanoFlu.
Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
Vaxart Gets New CEO, Focuses on Coronavirus Vaccine Program
by Zacks Equity Research
Vaxart (VXRT) management names Andrei Floroiu as its next chief executive officer with immediate effect. Stock appreciates on this news.
Emergent (EBS) to Manufacture AstraZeneca's Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) inks a deal with AstraZeneca to provide its CDMO services for supporting the manufacturing of the latter's COVID-19 vaccine candidate, AZD1222.
Novavax (NVAX) Stock Moves -1.18%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $44.43, marking a -1.18% move from the previous day.
J&J to Begin Human Study on Coronavirus Vaccine in July
by Zacks Equity Research
J&J's (JNJ) goal is to supply more than 1 billion doses of the vaccine globally if it proves to be safe and effective.
Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan
by Zacks Equity Research
Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.
Company News for June 8, 2020
by Zacks Equity Research
Companies In The News Are: AVGO, RH, SAIC, NVAX.
Novavax Clinches $60M Defense Contract for Coronavirus Vaccine
by Zacks Equity Research
Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.
Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Best-Performing ETFs of Last Week
by Sweta Killa
While the rally was broad-based, airline and banking industry led the way higher last week.
5 Top Stocks Up 100%+ in May With More Room to Run
by Tirthankar Chakraborty
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
Here's Why You Should Invest in Momentum ETFs Now
by Sweta Jaiswal, FRM
Here we discuss whether the market conditions are more conducive to investing in momentum ETFs.
5 Reasons to Bet on Growth ETFs
by Sanghamitra Saha
A few upbeat developments on the vaccine front, unprecedented economic help, reopening of economies and a few bullish economic datapoints should facilitate growth stocks ahead.
5 High Beta ETFs That Are in High Momentum
by Sanghamitra Saha
Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta ETFs that are in high momentum should gain ahead.
Biotech ETFs Soaring on COVID-19 Vaccine Progress
by Sweta Jaiswal, FRM
Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.